EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors

Status Recruiting

Clinical Trial Summary

The present study aims to evaluate the feasibility, safety and efficacy of EUS-FNI for MEN1-related pNETs

Clinical Trial Description

The management of multiple endocrine neoplasia type 1 (MEN1-1)-related pancreatic neuroendocrine tumors (pNETs) remains controversial. In general, surgical resection is currently the first-line therapy for MEN1-1-related pNETs. However, the surgical resection of pNETs is conditional for specific patients, and the incidence of postoperative adverse events is still high. Recently, several studies have demonstrated that endoscopic ultrasonography (EUS)-guided fine-needle injection (EUS-FNI) with ethanol or lauromacrogol may provide an alternative to surgical resection of pNETs. Nevertheless, their sample size was relatively small and conclusions were drawn based on short-term results. Therefore, a multicenter prospective study is being performed to further access the efficacy and safety of EUS-FNI for MEN1-1-related pNETs. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05554744
Study type	Interventional
Source	Guangxi Medical University
Contact	Shanyu Qin, MD,Ph.D
Phone	86-771-5353725
Email	qsy0511@163.com
Status	Recruiting
Phase	N/A
Start date	June 18, 2015
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05566093` - EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors	N/A
Completed	`NCT00970970` - Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease	N/A
Recruiting	`NCT05568017` - Neoadjuvant PRRT With Y-90-DOTATOC in pNET	Phase 2
Not yet recruiting	`NCT06024343` - Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction	N/A
Recruiting	`NCT03891784` - Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors	Phase 2
Recruiting	`NCT03204019` - A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor	Phase 2
Completed	`NCT00804336` - Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors	Phase 1
Recruiting	`NCT05997056` - Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors	Phase 2
Not yet recruiting	`NCT06158516` - A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors	Phase 2
Recruiting	`NCT04119024` - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma	Phase 1
Recruiting	`NCT05040360` - Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors	Phase 2
Completed	`NCT00576680` - RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors	Phase 1/Phase 2
Recruiting	`NCT05610826` - Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver	Phase 1/Phase 2
Active, not recruiting	`NCT03074513` - Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors	Phase 2
Completed	`NCT03967951` - CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms
Completed	`NCT01024387` - AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors	Phase 2
Not yet recruiting	`NCT03435770` - Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms	N/A
Recruiting	`NCT04134832` - Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region
Completed	`NCT02159989` - Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Phase 1
Active, not recruiting	`NCT04505553` - Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer	Phase 2